An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Status:
Terminated
Trial end date:
2019-02-27
Target enrollment:
Participant gender:
Summary
This was a study of INCB052793 given to patients with advanced malignancies that was to be
conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and
Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine).
Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).